Thus, the potential safety, tolerability and precise efficacy of KCC2 potentiation therapy is ideally suited for rapid titration and oral chronic treatment, as required and preferred for many epilepsy, neuropathic pain and other patients with chronic or age-related neurological disorders. This evidence concerns the gene SLC12A5 and epilepsy.